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Infective processes in the brain, spinal cord and meninges 
are considered to be the main causes of encephalitis, myelitis 
and meningitis. However, most cases remain unexplained. The 
incidence of different viral aetiologies (zoonotic and non-zoonotic) 
is especially poorly estimated, due to the lack of a standard 
case definition and of agreed diagnostic algorithms, including 
harmonised diagnostic methods and sample collection. It is 
important to clarify the incidence of viral encephalitis/meningitis 
and to optimise the diagnosis of infectious neurological illness, 
particularly to ensure early recognition of outbreaks or emerging 
infections such as West Nile encephalitis. The European Network 
for Diagnostics of ‘Imported’ Viral Diseases (ENIVD) has analysed 
the present surveillance situation for viral encephalitis/meningitis 
in Europe. Here we give an overview of the existing epidemiological 
sources of information in European Union (EU) Member States, 
mapping the laboratory capacity and identifying key requirements 
for a possible future surveillance study at European level. The data 
presented will help design a harmonised/standardised Europe-wide 
surveillance study investigating patients with encephalitis and/
or meningitis in order to obtain more information on the role of 
infections in these rarely analysed syndromes, both from a clinical 
and an epidemiological perspective. 
Introduction 
Encephalitis is an irritation and inflammation of the brain 
parenchyma, associated with clinical evidence of brain dysfunction 
[1]. It often coexists with inflammation of the covering membranes 
of the brain and spinal cord (meningo-encephalitis). Meningeal 
irritation (e.g. fever, headache, general malaise, vomiting) and 
somnolence are signs of meningitis, while behavioural, cognitive 
and focal neurological symptoms and seizures are signs of the 
disruption of brain function. Like meningitis, encephalitis can be 
caused by a wide variety of infectious agents, including viruses, 
bacteria, fungi and parasites (Table 1). Those cases of aseptic 
encephalitis for which the aetiology can be determined are most 
often caused by viral infections: herpes simplex viruses (HSV), 
varicella-zoster virus (VZV), Epstein-Barr virus (EBV), mumps 
virus, measles virus and enteroviruses are considered to be the 
major causes of viral encephalitis in immunocompetent individuals 
worldwide [2-5]. In addition to these common pathogens, which 
occur throughout Europe, arthropod-borne viruses (transmitted 
through insect and tick bites) can cause arboviral encephalitis 
with similar symptoms as herpes simplex encephalitis [6]. In 
Europe, the most important pathogens responsible for arboviral 
encephalitis are tick-borne encephalitis virus (TBEV), West Nile 
virus (WNV) and Sandfly fever virus (SFV) [7]. Important non-
arthropod-borne viral zoonotic pathogens affecting the central 
nervous system (CNS) are lymphocytic choriomeningitis virus 
(LCMV), rabies virus and Nipah virus. In regions where they are 
endemic, illness due to these pathogens may be correctly diagnosed 
because clinicians will consider them in their differential diagnosis. 
However, it is more than likely that incursions of these viruses 
(with the probable exception of rabies virus) into new regions 
would not be diagnosed unless the number of cases increased to 
unusual levels. A fact sheet concerning epidemiological, clinical, 
diagnostic and treatment data for the most important viruses that 
may cause (meningo-) encephalitis is available at ENIVD’s website, 
http://www.enivd.org. 
Despite improvements in the diagnosis of viral encephalitis, 
including cerebrospinal fluid (CSF) PCR [8], the aetiology of 
up to 75% of encephalitis cases remained unknown in recent 
surveys [4]. This issue is challenging when considering early 
detection of new and (re-) emerging pathogens such as WNV [6,9] 
or potential outbreaks caused by deliberate release of pathogens 
[10]. An accurate diagnosis is important for surveillance activities 
aimed at clarifying the aetiological pattern of viral encephalitis/
meningitis. However, this is impossible to achieve as long as routine 
investigations do not include the most common pathogens in a 
standardised manner. Moreover, a correct (differentiated) immediate 
diagnosis and the introduction of symptomatic or specific therapy 
may have a decisive influence on survival of patients, and may 
reduce the extent of brain injury. 
Four studies are currently being conducted in Europe, aimed 
at clarifying the incidence of viral encephalitis/meningitis in 
humans at national level and obtaining more valid clinical and 
epidemiological data. Details on these studies are available from 
the following publications and websites: 
1. A multi-centre prospective study to clarify the aetiology of 
encephalitis in England (2005-2008): http://www.hpa.org.uk/
infections/topics_az/encephalitis/study.htm 
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2. The Meningitis/Encephalitis registration study in Lower Saxony, 
Germany (MERIN, 2003-open) and the German enterovirus 
surveillance study (2005-2007): http://www.nlga.niedersachsen.
de 
3. Epidemiological study to optimise the diagnosis and prognosis 
of encephalitis infections in France (2007): http://www.invs.
sante.fr/surveillance/encephalites_2007/default.htm 
4. A systematic laboratory-based surveillance of unexplained 
neurological illness to rule out flavivirus infection in The 
Netherlands [9].
ENIVD’s current project involves a preliminary survey regarding 
the epidemiological situation of viral encephalitis in EU Member 
States. It is meant to identify the requirements for a possible future 
surveillance study at European level, as well as to improve the 
diagnostic methods and to carefully monitor the present situation 
especially regarding WNV, TBEV and SFV as potential emerging 
arboviral causes of encephalitis. The activities concerning the 
improvement of diagnostics and surveillance data planned by the 
individual ENIVD working groups for those arboviral pathogens will 
be presented in separate publications. In this study, the ENIVD 
working group for viral CNS diseases presents the results of a 
preliminary survey of the existing surveillance systems in Europe. 
A number of important issues are considered that will need to be 
addressed when designing a surveillance study on the aetiological 
pattern of viral encephalitis/meningitis at European level. 
Methods
This preliminary data survey was performed from May 2006 to April 
2007. PubMed (the United States’ National Library of Medicine) was 
searched for relevant papers published between 1996 and 2006. 
The search terms selected were: “meningitis/encephalitis survey”, 
“meningitis/encephalitis surveillance”, “meningitis/encephalitis 
study”, “meningitis/encephalitis epidemiology”, and “meningitis/
encephalitis diagnostics”. Furthermore, epidemiological data were 
collected via internet searches or requested from national contact 
points by e-mail. The data were reported by national and/or regional 
public health authorities for infectious disease control (ministries 
of health, public health institutes and/or reference laboratories) or 
other organisations or networks (e.g. the International Scientific 
Working Group on Tick-borne Encephalitis) focussing on pathogens 
affecting the CNS. We decided to search/ask only for data from 
2004 because this was the most recent year for which all datasets 
were completed and proofed. We focussed on “reported cases 
of bacterial meningitis/encephalitis”, “reported cases of viral 
meningitis/encephalitis”, and “reported cases of other or unknown 
aetiology”. 
t a b l e  1
The most important infections causing central nervous system disease*
Meningitis Encephalitis/ Meningo-encephalitis
Viral (aseptic meningitis) Viral
Enteroviruses Herpes simplex virus
Tick-borne encephalitis  virus and other arboviruses† Varicella-zoster virus
Mumps virus Epstein-Barr virus
Herpesviruses Mumps virus
Human immunodeficiency virus Measles virus
Influenzaviruses Enteroviruses
Parainfluenza virus West Nile virus
Measles virus Tick-borne encephalitis virus
Rotavirus Other arboviruses†
Lymphocytic choriomeningitis virus Human immunodeficiency virus
Rabies virus
Bacterial (septic meningitis) Bacterial
Haemophilus influenzae b Listeria monocytogenes
Neisseria meningitidis Mycobacterium tuberculosis
Streptococcus pneumoniae Mycoplasma pneumoniae
Staphylococcus spp. Borrelia spp.






Cryptococcus neoformans Cryptococcus neoformans
Parasitic Parasitic
Acanthamoeba spp. Acanthamoeba spp.
Toxoplasma gondii Naegleria spp.
* adapted from: www.meduniwien.ac.at/hygiene; www.enivd.de/ENCDISEASES/fs_encdiseases.htm
†  Arbovirus = arthropod-borne virus (e.g. Toscana virus)
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The data were collected, analysed and verified by the national 
contact points in order to: 
• gain an overview of the epidemiological situation in the EU 
Member States, 
• identify existing resources that would be available in the event 
of a surveillance study (e.g. surveillance systems, public health 
institutes, clinical networks, hospitals, officially appointed 
laboratories, epidemiologists), 
• review in particular the data on the causes of unknown 
aetiologies, 
• and develop hypotheses on the reasons why these aetiologies 
are unknown. 
Moreover, an expert meeting on diagnostics and surveillance of 
viral (meningo-) encephalitis held in Berlin in April 2006 provided 
information on previous, ongoing or planned national studies in six 
Member States that dealt with the incidence of the most relevant 
aetiologies of viral encephalitis/meningitis. The experiences gained 
from these studies are summarised here and should be taken into 
account in a possible future European surveillance study. This 
work included the selection of suitable partner institutions and 
clarification of whether samples would be available for further 
diagnostic investigation with special regard to the manner of sample 
collection. Furthermore, we defined the sample numbers necessary 
for such a study as well as established and evaluated diagnostic 
assays for the detection of different encephalitis-causing viral 
pathogens. 
Results 
The epidemiological situation of CNS diseases in Europe
The most recent epidemiological situation regarding CNS 
infections/syndromes in the 27 EU Member States (EU-27), based 
on disease notifications in 2004, is shown in Table 2. Bacterial 
causes of meningitis/encephalitis are thoroughly investigated in all 
Member States, at least judged by the presence of well-established 
surveillance infrastructures [11], and data were provided for all 
countries except for Belgium. In contrast, notification of viral 
meningitis/encephalitis cases differs between the countries 
because reporting policies are neither standardised nor rigorously 
enforced. 
Although geographical differences in the occurrence of viral 
pathogens (either more common or endemic viruses) are likely 
to play a role, the variation in the incidence of viral meningitis/
encephalitis across Europe that was seen in this survey is probably 
due to differences in the surveillance systems. One reason could 
be the lack of a Europe-wide standard case definition for viral CNS 
syndromes. Moreover, the spectrum of relevant viral pathogens 
reported in the surveillance systems depends on the spread of the 
diagnostic panels and/or notification regulations, and is therefore 
also very divergent. 
The available diagnostic information was poor. Only few 
countries – namely Austria, the Czech Republic, Hungary, Poland, 
Slovakia, and Slovenia – could provide pathogen-specific data 
for more common (e.g. Herpesviruses) and endemic (e.g. TBEV) 
viral aetiologies. Those countries have or had a special endemic 
situation, and consequently a higher awareness of arboviral CNS 
diseases (in particular tick-transmitted ones). They may also be 
countries with a stronger interest to differentiate between more 
common and endemic aetiologies whose clinical pictures can be 
very similar. 
Other countries only reported pathogen-specific data for major 
arboviral neurological diseases, like TBEV (e.g. the Baltic States, 
Germany and Finland) and WNV infections (e.g. Romania), without 
further differentiated reporting of other more common causes. 
Although endemic in several European countries, TBEV surveillance 
is not uniform nor always mandatory in Europe [12]. 
Only 15 (56%) of the 27 Member States provided some level 
of information on unexplained neurological illnesses of possible 
infectious aetiology. The lack of information on non-notifiable 
CNS syndromes in the other 12 countries indicates a data gap in 
surveillance. It is likely that more information is available on regional 
level or from surveys. This may be the case for enteroviruses, since 
all countries are obliged to document the absence of poliovirus 
circulation as part of the global eradication effort, but the data 
are not always publicly available. The Netherlands, for instance, 
has a continuous laboratory-based enterovirus surveillance that 
processes approximately 3,000 samples per from patients with 
meningitis per year. On average, 10% of those samples contain 
enterovirus. In addition, 400 cases are hospitalised with suspected 
viral meningitis in the Netherlands annually, 60 with suspected 
viral encephalitis, and 255 with encephalitis of unknown origin. 
“Suspected” means that the diagnosis derived from CSF could 
not be confirmed by virus detection or serology. However, the lack 
of data regarding the proportion of cases with other or unknown 
aetiology in the official notification report also makes a comparison 
among European countries difficult. 
Existing expertise on CNS diseases in Europe
Based on literature and internet searches, we compiled a database 
of the specific diagnostic and/or epidemiological capacities and 
functions in European institutions and microbiological reference 
laboratories. The database has been updated regularly since the 
beginning of 2006, and includes 112 reference laboratories from 
the 27 EU Member States, covering the main bacterial and viral 
aetiologies of CNS infections (Table 3). 
The number of staff employed in the diagnosis and control of 
infectious diseases who also handle pathogens that cause CNS 
disease ranged from five to 419 in the different Member States 
(including microbiologists and epidemiologists). The size of the 
groups can vary, depending on whether single groups/units or 
whole departments were described. The people working in these 
departments are often responsible for more than one kind of 
pathogen or disease. We have compiled a contact database with 
postal and e-mail addresses that also includes detailed information 
on the groups’ capacities. The information can be provided on 
request. 
The Czech Republic and Germany have the largest number 
of reference laboratories for pathogens causing CNS disease, 
followed by France and Belgium. Cyprus, Germany, Portugal and 
the United Kingdom have groups specialised in the diagnostics 
of viral CNS infections and syndromes. Of the 112 identified 
laboratories, 72 (64%) provide training activities for students 
and/or professional personnel. Seventy-eight laboratories (70%) 
organise and/or participate in external quality assurance (EQA) 
studies. However, only 31 (28%) laboratories were involved in 
outbreak investigations. 
The most frequently reported techniques/activities with respect 
to the reference pathogens/diseases are antibody detection (69% of 





Reported cases of bacterial 
meningitis/encephalitis 
(incidence/100,000)
Reported cases of viral 
meningitis/encephalitis 
(incidence/100,000)
Cases of other or unknown 
aetiology Reference
Austria 8,171
total: 126 total: 59
20 bacterial meningitis;
14 viral meningo-encephalitis
Federal Ministry of Health, Family 
and Youth, BMGFJ, Austria mostly MNC (1.02); PNC (0.42) TBE (0.66); Herpes (0.04); Measles (0.02)
Belgium 10,400 not available$ not available$ not available$ Scientific Institute of Public Health, IPH, Belgium
Bulgaria 7,780
total: 95 total: 699
163 bacterial meningitis National Centre of Health Informatics, NCHI, Bulgariamostly MNCb (0.46); PNC (0.40) without further informationc
Cyprus 826
total: 5 total: 20
9 other bacterial meningitis Ministry of Health, Republic of Cyprus MNC (0.61) without further informationc
Czech Republic 10,229
total: 119 total: 667
166 other bacterial meningitis;
668 viral meningo-encephalitis
National Reference Centre for 
analysis of epidemiological data, 
NRC/SZU, Czech Republic MNC
b (0.96); 
HIBb (0.21)  TBE (4.96) ; EV (1.56)
Denmark 5,414
total: 266




18 other and unknown aetiology Health Protection Inspectorate, Estonia HIB (0.97); MNC (0.38) TBE (13.63)
Finland 5,235
total: 1,117 total: 29
not available National Public Health Institute, KTL, Finlandmostly STCb (20.48); MNCb (0.84) TBE (0.55)
 France 60,257
total: 1,439†
no cases reportedc not available National Public Health Institute, InVS, Francemostly STC (1.46); MNC (0.73)
Germany 82,645
total: 531 total: 125
not available Robert Koch Institute, RKI, Germany
mostly MNC (0.46); NB (0.6)‡ TBE (0.15) 
Greece 11,098
total: 168 total: 199 376 bacterial meningitis / 
encephalitis;
177 other and unspecified 
aetiologies
Hellenic Centre for Infectious 
Diseases Control, KEEL, Greecemostly MNC (0.80); PNC (0.64) without further informationc
Hungary 10,124
total: 201 total: 122
64 infectious encephalitis;
148 meningitis
National Centre for Epidemiology, 
OEK, Hungarymostly PNC (0.75); MNC (0.42)
TBE (0.75); 
Herpes (0.16); EV (0.15); WNV 
(0.03) etc.
Ireland 4,080
total: 225 total: 28
36 other bacterial meningitis Health Protection Surveillance Centre, HPSC, Irelandmostly MNCb (4.85); PNC (0.54) without further informationc
Italy 58,033
total: 748 total: 434
236 bacterial meningitis National Public Health Institute, ISS, Italymostly MNC (0.59); STC (0.58) without further informationc
Latvia 2,318
total: 25 total: 251
not available State Agency “Public Health Agency”, SVA, Latvia MNCb (1.04); 
HIBb (0.04) TBE (10.83)
Lithuania 3,443
total: 101 total: 425
not available
Centre for Communicable Disease 
Prevention and Control, ULPKC, 
Lithuania MNC
b (2.67);
HIBb (0.26) TBE (12.34)
Luxembourg 459
total: 0
no cases reportedc not available Ministry of Health, Health Management, Luxembourg no cases in 2004, in previous years 
N. meningitidis
Malta 400
total: 15 total: 2
5 bacterial meningitis Ministry of Health, Public Health Department, DSU, Maltamostly PNC (1.75); MNC (1.00) without further informationc
Poland 38,559
total: 433 total: 308§ 512 bacterial, 1,119 viral 
meningitis/encephalitis; 
353 other and unspecified 
aetiologies
National Institute of Hygiene, PZH, 
Poland mostly MNC (0.31); HIB (0.19) TBE (0.68)
Portugal 10,441
total: 91
no cases reportedc not available National Public Health Institute, DGS, Portugal MNC (0.81); HIB (0.06)
Romania 21,790
total: 467 total: 989c
not available Institute of Public Health, ISPB, Romania MNC (1.13) WN meningitis  (0.01)
Slovakia 5,401
total: 81 total: 207 103 bacterial meningitis; 
40 unknown viral meningitis / 
encephalitis
Public Health Authority of the Slovak 
Republic MNC (0.58); PNC (0.41) TBE (1.29); Herpes (0.19); VZV (0.17) etc.
Slovenia 1,967
total: 29 total: 232 25 bacterial meningitis / 
encephalitis; 
187 unknown viral meningitis / 
encephalitis
Public Health Institute of the 
Republic Sloveniamostly STC (0.81); MNC (0.31) mostly TBE (10.37); Herpes (0.76) 
Spain 42,646
total: 881
no cases reportedc not available National Public Health Institute Carlos III, ISCIII-CNE, SpainMNCb (2.22)
Sweden 9,008
total: 565 total: 222




no cases reportedc not available National Institute of Health and the Environment, RIVM, NetherlandsMNCb (1.83) 
United 
Kingdom 59,479
total: 916 total: 217
294 meningitis Health Protection Agency, HPA, UK
mostly MNC (0.93); PNC (0.29) without further informationc
* As reported by the national/regional public health authorities for infectious disease control (ministries of health, public health institutes, reference laboratories). When comparing the data 
across countries, please note that reporting criteria may vary. Incidence rates were calculated per 100,000 inhabitants.
a General public health statistics: http://www.who.int/about/regions/euro/en/index.html
b Classified as invasive bacterial disease with a broad case definition (including cases of meningitis and septicaemia).
c TBE is not a notifiable disease in this country.
$ Data are not available due to incomplete surveillance network.
† Number of cases adjusted for the coverage of a clinical laboratory network as well as corrected for under-notification and incidences calculated per 100,000 inhabitants for meningitides 
with or without bacteraemia, Epibac 2004, Metropolitan, France (http://www.invs.sante.fr/surveillance/epibac/default.htm).
‡ Incidence is based on the notification from six federal states (Berlin, Brandenburg, Mecklenburg Western Pomerania, Saxony, Saxony-Anhalt and Thuringia) with a total of 13,433,358 
inhabitants.
§ Until 2005 meningitis in the course of other infectious diseases such as mumps were not reported.
EV: Enteroviruses; HIB: H. influenzae type b; MNC: Meningococci; NB: Neuroborreliosis; PNC: Pneumococci; STC: Streptococcus spec.; TBE: Tick-borne encephalitis; VZV: Varicella-zoster virus; 
WN(V): West Nile (virus).
T a b l e  2
Epidemiological data: notifications of meningitis and encephalitis in Europe (EU-27) caused by bacterial and viral agents, 
reported in 2004* 
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Member State Number of ref. labs Pathogens-








Number of labs 
involved in 
outbreak situation
Austria 5 LB; HIB; MMR; MNC; PNC; Polio virus; TBEV; other relevant viruses 60 5 4 (1)
a 2
Belgium 10 (2)a LB; EV; HIB; Morbilliviruses; MNC; Polio virus; Rabies virus; PNC; TBEV; WNV > 98 6 (2)
a 6 (4)a 1 (2)a
Bulgaria 9 LB; MNC; STC; EV; MMR; Herpesviruses; other pathogens 56 3 7 (2)
a 1
Cyprus 2† EV, Herpesviruses (viral meningitis); other relevant pathogens (MNC, PNC, HIB) > 5 1 not reported not reported
Czech 
Republic 14
STC; MNC; HIB; Herpesviruses; MMR; EV; LB; 
Arboviruses (incl. TBEV); other relevant 
pathogens
172 11 12 (2)a 1
Denmark 2 EV; MMR; other relevant viruses; PNC; other relevant bacteria 241 2 2 1
Estonia 3 (1)a MNC; HIB; LB; other bacteria; TBEV; EV; other viruses 25 not reported 2 (1)
a not reported
Finland 4 PNC; MNC; HIB; EV; MMR; M.tuberculosis; Arboviruses; other relevant pathogens 375 1 4 1
France 10 Arboviruses; LB; EV; HIB; Listeria; Measles virus; MNC; PNC; Rabies virus; STC 154 5 5 (5)
a 3
Germany 11
LB; MNC; STC; MMR; EV; HIB; Herpes 
virus; VZV; Rabies virus; TBEV; viral CNS 
infections
175 7 6 (5)a 4
Greece 3 (1)a MNC; STC; HIB; other relevant viruses > 16 1(1)a 2(1)a 2(1)a
Hungary 2 MNC; EV; other relevant pathogens 49 2 2 not reported
Ireland 2 (1)a MNC; HIB; other relevant viruses > 17 1(1)a 1(1)a 1(1)a
Italy 2 LB; EV; HIB; MNC; STC; other relevant pathogens 419 2 1(1)
a 1
Latvia 1 TBEV; LB; Herpes virus; CNS bacterial infections > 35 1 1 not reported
Lithuania 1 LB; EV; TBEV; Herpes virus; Measles virus; other relevant viruses 24 not reported 1 not reported
Luxembourg 1 MNC; HIB; Measles virus; other relevant pathogens 25 1 not reported not reported
Malta 1 PNC; HIB; MNC; other relevant pathogens 11 1 not reported 1
Poland 3 STC; Herpesviruses, EV; Arboviruses; bacterial meningitis (incl. MNC and HIB) > 4 3 2 (1)
a not reported
Portugal 3
MNC; HIB; Viral CNS infections; vector-
borne pathogens (i.e. Borrelia, WNV); other 
relevant pathogens
144 3 3 3
Romania 1 LB; STC; MNC; HIB; vector-borne diseases; other relevant pathogens 31 1 1 not reported
Slovakia 3 MNC; HIB; Arboviruses; other relevant pathogens 152 1 2(1)
a not reported
Slovenia 2 (1)a MNC; HIB; Arboviruses; other relevant pathogens (incl. TBEV, STC) > 92 1(1)
a 1(1)a not reported
Spain 6
MNC; PNC; HIB; Herpes-, Entero-, and 
Arboviruses; other relevant viral 
pathogens
18 6 6 6
Sweden 3 MNC; other relevant pathogens 404 2 3 not reported
The 
Netherlands 2
Bacterial meningitis; other relevant 




a LB; MNC; STC; HIB; viral CNS infections; 
other relevant pathogens > 100 4 3 (3)
a 3
* Represents laboratories officially designated as reference laboratories (Ref. labs) for the specific pathogens/diseases, or laboratories that act as national reference 
centres without being officially recognised as such. Even though these laboratories are considered as a resource at national/international level by their national 
public health authorities, the definition of “laboratory” can vary across countries as it can include groups of different size. The number of laboratories per se 
should therefore be read with caution and additional information should be sought. 
a Not all laboratories have presented data regarding their capacities/activities. The number in brackets shows the number of laboratories without further information 
(partial/complete).
† Reference laboratory services for MNC are done by a group in another Member State.
EQA: external quality assurance; CNS: Central nervous system; EV: Enteroviruses; HIB: H. influenzae type b; LB: Lyme borreliosis; MMR: Measles, Mumps and Rubella; 
MNC: Meningococci; PNC: Pneumococci; STC: Streptococcus spec.; TBEV: Tick-borne encephalitis virus; VZV: Varicella-zoster virus; WNV: West Nile virus
t a b l e  3
List of existing resources for the surveillance of meningitis and encephalitis in Europe (EU-27) (data as reported)*
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† Ref. [5]; ‡ ISIS database, RIVM, The Netherlands; § Data from PMSI and InVS, France.
CMV: Cytomegalovirus; EBV: Epstein-Barr virus; HHV-6: Human herpes virus 6; HSV: Herpes simplex virus; LCMV: Lymphocytic choriomeningitis virus; TBEV: Tick-borne 
encephalitis virus; VZV: Varicella-zoster virus; WNV: West Nile virus.
CFT: Complement fixation test; CNS: Central nervous system; CSF: Cerebrospinal fluid; EIA: Enzyme immunoassay; SISPA: Sequence independent single primer 
amplification.
T a b l e  4
Overview of six different studies at national level to clarify the aetiology of viral encephalitis/meningitis
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subtyping (64%), antibiotic resistance/immunity testing (55%), 
isolation of reference pathogens (53%), microbiological analyses 
(46%), antigen detection (40%), providing reference material, e.g. 
diagnostic reagents (23%) and electron microscopy (11%) (data 
not shown). 
Key conditions for a future surveillance study at the European level
Based on the expert meeting in Berlin in 2006, data were 
obtained from previous, ongoing or planned studies in six Member 
States in order to clarify the incidence of the most relevant 
aetiologies of viral encephalitis/meningitis at national level. Table 
4 shows a broad variability among these studies concerning the 
pathogens they focussed on, the type of samples they used, the 
diagnostic methods they applied and the determined or calculated 
rate of unknown aetiology. 
The consensus was that comparative data for the incidence of 
most viral agents of human (meningo-) encephalitis is missing. The 
proportion of cases with unknown aetiology ranged from 30% to 
80% in the presented studies. The reasons for unknown diagnosis 
could be traced to either a failure of the diagnostic tests or an 
inappropriate case definition, resulting in under-ascertainment of 
both known viruses and “new” viruses. 
The following issues were considered during the expert meeting 
in order to design a possible future surveillance study for viral 
(meningo-) encephalitis at the European level: 
Case definition
The diagnosis of encephalitis is often difficult to establish, since 
many other clinical conditions may mimic encephalitis. In addition, 
several arboviruses can cause a range of neurological syndromes, 
including meningitis or paralytic illness. Therefore, a broad case 
definition will be necessary in order to capture all relevant cases of 
acute and suspected CNS diseases (meningitis, encephalomyelitis 
and encephalitis) in the first stage of a study. To date, there is no 
standard clinical case definition that includes all relevant types of 
infectious CNS diseases, although this would be practical from a 
clinical perspective. A limited case definition (e.g. one that excludes 
signs of aseptic meningitis) could lead to under-ascertainment of 
relevant cases. A distinction between the different disease types 
with the final goal of identifying a specific aetiological agent could 
be achieved in following processes. To harmonise the clinical and 
diagnostic approaches in a European study, all personnel involved 
in case notification should be informed of such a standard case 
definition and should be provided with a protocol for stringent data 
management and diagnostic algorithms. It may become necessary 
to adapt specific case definitions to the situation in different 
countries, for example if certain pathogens are endemic in some 
but not other areas. Therefore, the EU case definitions currently 
being finalised by the European Centre for Disease Prevention and 
Control (ECDC) should be taken into account. 
Sample collection and storage
Regarding the collection of samples, it should be considered 
that other types of samples besides CSF (e.g. sera, faeces, throat 
swabs) are also important when trying to detect a broad spectrum 
of relevant pathogens. Basic clinical information should always 
be provided with the sample material. A minimum dataset should 
include: age, gender, domicile of the patient, date of onset/duration 
of the complaints, type of complaints, travel history, vaccination 
history (e.g. against yellow fever, Japanese encephalitis) and context 
of the current epidemiological situation (e.g. outbreak, cluster).
Follow-up studies may become necessary, for example if clinical 
intervention measures become available in the future or new 
pathogens are discovered. Therefore, samples of selected cases 
should be shipped to a central archive, aliquoted and stored at 
-70°C to avoid damage of the material by frequent thawing. Sample 
collection along with the recommended minimum dataset will be 
a valuable resource for later analysis of patients’ and diagnostic 
profiles. 
Diagnostic issues
A three-step model is suggested for diagnostic procedures in 
order to ensure comprehensive diagnostic investigation. The first 
step should include the local medical investigation and usual 
analysis (PCR and serology) of acute cases by clinical laboratories. 
Clinical and epidemiological features (e.g. occupation, travel history 
or animal contact) should be collected at this level for differential 
diagnostic approaches. The second step comprises the extended 
analysis of suspected cases by reference laboratories for commonly 
recognised causes of (meningo-) encephalitis, and of less commonly 
recognised and travel-related causes when indicated. The third step 
includes the identification of specific pathogens (e.g. by new typing 
methods) in cases of unknown aetiology, as well as the collection 
of selected samples by reference laboratories and storage in a 
centralised archive for future use. 
Standard operating procedures for testing should be shared 
among all participating laboratories and regularly monitored by EQA 
programmes to ensure diagnostic consistency. In its current project, 
the ENIVD has begun EQA studies for the diagnostics of TBEV and 
WNV [13-15], and further studies on arboviral aetiologies of CNS 
diseases are planned [16]. Moreover, it might be advantageous to 
consider the new multiplex-microarray technology presented in the 
Finnish study (see Table 4) [17,18] in a broad European study on 
viral CNS diseases. This would guarantee a unique analysis platform 
for all participating laboratories by including the more common 
pathogens of viral CNS diseases (e.g. HSV, VZV, enteroviruses) 
as well as relevant viral zoonotic agents (e.g. TBEV, WNV, rabies 
virus) according to the regional/endemic situation of the European 
countries or on special request. 
Data management 
A prerequisite for a surveillance study at European level – in 
which data from numerous countries are pooled – seems to be the 
establishment of a central hub recording and managing the entire 
study data (patients’ clinical and epidemiological data, and CNS 
diagnostic data). To ensure standardised reporting, ICD-10 coding 
is recommended in addition to the broad case definition. 
A general problem in most of the national studies presented 
here was the failure of clinicians to report clinical cases. The 
contribution of the individual clinicians regarding the provision of 
clinical data and material varied greatly depending on hospital and 
medical branch (paediatricians, for example, seemed to be more 
cooperative than neurologists). Efforts to reach a final aetiological 
diagnosis are not always considered essential, for instance when 
all patients diagnosed with viral encephalitis are routinely given 
the same antiviral therapy. The success of a study depends on 
the voluntary cooperation of hospitals and clinicians. One of the 
important issues is to motivate them, for example by offering 
clinicians and public health officers open access to evaluated and 
updated study data on the internet or free diagnostic tests. 
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Ethical and data protection issues
Ethical issues regarding patient data will be especially relevant 
in follow-up studies. These concerns might not be important 
during the first contact when diagnostic analysis for the aetiology 
of CNS disease is requested by clinicians. Nevertheless, all further 
analysis will require a patient agreement. It became clear during 
the expert meeting that this is handled quite differently in the 
European countries. This aspect therefore needs special attention 
in planning a European study and should be discussed with the 
different European public health authorities. 
Number of samples necessary for a European study
According to the data available, the UK study recorded 
approximately 100 cases of viral encephalitis per year. This covers 
an estimated 60% of all cases of viral CNS disease in England. 
The experts give a ratio of 1:2:0.5 cases for encephalitis:mening
itis:encephalomyelitis. The true number of all cases of viral CNS 
disease, based on a broad case definition as recommended above, 
is therefore five- to six-fold higher than the number of recorded 
cases. For the UK study, this was calculated to be approximately 
700 cases. Based on this calculation, the expected number of viral 
CNS disease cases in a given country can be estimated by taking 
T a b l e  5
Estimated number of cases for a possible future study on viral central nervous system diseases in Europe*
Country Population                            (x1000)a
Total expected  number of 
cases per year
Number of cases              
per 105 inhabitants
Number of cases for 60 % 
coverage
     
England 50.431† 700 1.39 420
Austria 8,189 340b 4.15 200
Belgium 10,419 145 1.39 90
Bulgaria 7,726 990b 12.81 590
Cyprus 835 80b 9.58 50
Czech Republic 10,220 3,780b 36.97 2,270
Denmark 5,431 80 1.47 50
Estonia 1,330 250b 18.79 150
Finland 5,249 1,750‡ 33.34 1,050
France 60,496 4,170§ 6.89 2,500
Germany 82,689 1,800 2.18 1,080
Greece 11,120 275b 2.47 165
Hungary 10,098 370b 3.66 220
Ireland 4,148 100b 2.41 60
Italy 58,093 1,150 1.98 690
Latvia 2,307 310b 13.44 190
Lithuania 3,431 530b 15.45 320
Luxembourg 465 7 1.50 4
Malta 402 6 1.50 4
Poland 38,530 2,500b 6.49 1,500
Portugal 10,495 150 1.43 90
Romania 21,711 930b 4.28 560
Slovakia 5,401 430b 7.96 260
Slovenia 1,967 1,000b 50.84 600
Spain 43,064 850 1.98 510
Sweden 9,041 180 1.99 110
The Netherlands 16,299 1,330$ 8.16 800
Expected total: ~ 15.000
* Including encephalitis, meningitis, encephalomyelitis.
a With the exception of England, data adapted from: http://www.who.int/about/regions/euro/en/index.html (actual numbers)
b Estimation adapted to data from existing infectious disease reports of last years (‘04, ‘05 and/or ‘06), as available
† Source: http://www.statistics.gov.uk/CCI/nugget.asp?ID=6 (last mid-year population estimates from UK)
‡ Estimation based on data from Ref. [5].
§ Estimation based on data as presented for the French study.
$ Estimation based on data as presented for the Dutch study.
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into account the respective population (with or without adaptation 
to existing differentiated epidemiological data) (Table 5). 
The calculated numbers are only rough estimations, but can be 
used as a general indication of how many samples, material and 
work would eventually be necessary to cover approximately 60% 
of all cases in the respective countries. Thus, these estimates 
may have a limited relevance to the actual incidence of viral CNS 
diseases in any country. 
However, the data in Table 5 show that a possible future study on 
viral CNS diseases at European level could be extensive regarding 
samples, logistics, material and costs, if all cases were analysed for 
all relevant aetiologies including differential diagnostics. 
Discussion
The incidence of most viral agents of human (meningo-) 
encephalitis is not estimated well by the surveillance systems of 
the various European countries. This harbours the risk that potential 
emerging infectious diseases, such as West Nile fever, will not 
be recognised in time by the existing surveillance infrastructures 
[19]. Pooling data from several countries may help identify and 
monitor emerging problems more quickly. Establishing a European 
surveillance system for viral encephalitis/meningitis by bundling 
the existing resources and introducing a harmonised/standardised 
reporting and diagnostic system will be challenging, but is essential, 
and not only for future preparedness and response issues. With 
more specific treatments or vaccines becoming available [1,20], 
it will also be of interest for pharmaceutical and vaccine-producing 
companies and public health institutions to carefully analyse the 
epidemiological situation, and to adapt therapeutic interventions 
as well as prevention strategies accordingly. A broad standard 
case definition and harmonised/standardised diagnostic algorithm 
using a multiplex-microarray system validated for a wide range of 
viruses may help to discover the true incidence and aetiological 
pattern of viral encephalitis/meningitis within each country. This 
would guarantee high performance and comparability of the results 
consistent with EQA programmes. To improve surveillance, it is also 
important to quantify the extent of cases of unknown aetiology, in 
order to allow a comparison of the data from each country and to 
identify possible weaknesses in the surveillance data. Therefore, 
clinicians must be motivated to report all cases of viral encephalitis/
meningitis and to reach a definitive aetiological diagnosis. 
A future study on viral CNS diseases at European level could be 
extensive in work load and costs; an alternative is a survey including 
only a small number of countries with experts willing to cooperate 
and to set up such a study, in order to improve the awareness 
and ascertainment of viral CNS diseases. Partners interested in 
collaborating in a European survey network on viral CNS diseases 
have already been identified in 13 countries in different European 
regions (the Czech Republic, Poland, Russia, Slovakia, Slovenia, 
France, Spain, Switzerland, Denmark, Finland, Germany, the 
Netherlands and United Kingdom). It is advisable to use the 
experience and knowledge of recently completed or ongoing studies 
at national level (see Table 4) to allow more detailed planning of a 
prospective European study on viral encephalitis/meningitis. 
A European study based on a close cooperation between 
clinicians, epidemiologists and microbiologists will provide more 
accurate and timely data on viral CNS diseases which are of 
public health interest. Such an initiative could help increase case 
ascertainment, reduce the rate of unknown aetiologies, develop and 
validate new diagnostic methods, improve recommendations and 
guidelines, and gain more valuable clinical and epidemiological 
data for research purposes.
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